Cargando…

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer

SIMPLE SUMMARY: HER2 is a marker known to be over-expressed on breast cancer, rendering it one of the most useful solid tumor targets for antibody-based therapies. Despite expression on ovarian cancer, results targeting HER2 in this setting have been disappointing, thus requiring more aggressive app...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vallera, Daniel A., Oh, Felix, Kodal, Behiye, Hinderlie, Peter, Geller, Melissa A., Miller, Jeffrey S., Felices, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394622/ https://www.ncbi.nlm.nih.gov/pubmed/34439149 http://dx.doi.org/10.3390/cancers13163994

Ejemplares similares

NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
por: Vallera, Daniel A., et al.
Publicado: (2020)

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer
por: Kennedy, Philippa R., et al.
Publicado: (2023)

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
por: Kaminski, Michael F, et al.
Publicado: (2022)

Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer
por: Felices, Martin, et al.
Publicado: (2023)

Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion
por: Myers, Jacob A., et al.
Publicado: (2022)

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
por: Schmohl, Jörg U., et al.
Publicado: (2017)

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells
por: Arvindam, Upasana Sunil, et al.
Publicado: (2020)

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
por: Schmohl, Joerg U., et al.
Publicado: (2016)

ARID5B regulates metabolic programming in human adaptive NK cells
por: Cichocki, Frank, et al.
Publicado: (2018)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review
por: Uppendahl, Locke D., et al.
Publicado: (2018)

Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation
por: Mishra, Hemant K., et al.
Publicado: (2021)

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
por: Oh, Felix, et al.
Publicado: (2018)

CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells
por: Schiller, Christian B., et al.
Publicado: (2016)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

Continuous engagement of a self-specific activation receptor induces NK cell tolerance
por: Tripathy, Sandeep K., et al.
Publicado: (2008)

Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
por: McNerney, Kevin O., et al.
Publicado: (2020)

Genetics for all: Tri-directional research engagement as an equitable framework for international partnerships
por: Billawala, Thalia, et al.
Publicado: (2022)

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity
por: Peipp, Matthias, et al.
Publicado: (2015)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
por: Oh, Felix, et al.
Publicado: (2020)

Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation
por: Yang, Jianbo, et al.
Publicado: (2021)

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
por: Guo, Zong Sheng, et al.
Publicado: (2020)

Peptide-specific engagement of the activating NK cell receptor KIR2DS1
por: Chapel, Anaïs, et al.
Publicado: (2017)

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
por: Hofland, Tom, et al.
Publicado: (2019)

Trying to Understand NK Cell Function in vivo Points towards a Severity Score for CVID Patients
por: Wehr, Claudia
Publicado: (2016)

Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors
por: Koch, Christine, et al.
Publicado: (2017)

Reduced Ovarian Function in Female Rheumatoid Arthritis Patients Trying to Conceive
por: Brouwer, Jenny, et al.
Publicado: (2019)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers
por: Bordoloi, Devivasha, et al.
Publicado: (2023)

Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer
por: Kennedy, Philippa R., et al.
Publicado: (2022)

NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer
por: Leung, Elaine Y.L., et al.
Publicado: (2020)

CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Nowak, Juliette, et al.
Publicado: (2023)

Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients
por: Hoogstad-van Evert, Janneke S., et al.
Publicado: (2018)

Commentary: Do not try this at home
por: Miller, Jacob R., et al.
Publicado: (2021)

Engagement of lymphoma T cell receptors causes accelerated growth and the secretion of an NK cell-inhibitory factor
por: Dubois, Sigrid, et al.
Publicado: (2020)

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples
por: Scott, Eleanor M., et al.
Publicado: (2019)

Human NK Cell Development: One Road or Many?
por: Cichocki, Frank, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_at8iklntgo9hbun8q0pnsdr0i3